Sex-based outcomes after PCI in high-bleeding risk patients: Results from the Onyx ONE Clear trial
Presenter
Roxana Mehran, M.D., MSCAI, Icahn School of Medicine at Mount Sinai, New York, NY
Roxana Mehran, M.D., MSCAI1, David E. Kandzari, M.D., FSCAI2, Ajay J. Kirtane, M.D., FSCAI3, Matthew J. Price, MD4, Daniel I. Simon, M.D.5, Azeem Latib, M.D., FSCAI6, Elvin Kedhi, MD, PhD7, Alexandre Abizaid, M.D.8, Azfar Zaman, MD9, Maria Parke10, Te-Hsin Lung10, Stephan Windecker, M.D.11 and Gregg W. Stone, M.D.12, (1)Icahn School of Medicine at Mount Sinai, New York, NY, (2)Piedmont Heart Institute, Atlanta, GA, (3)NewYork-Presbyterian Columbia University Irving Medical Center, New York, NY, (4)Scripps Clinic Medical Group, La Jolla, CA, (5)University Hospitals Cleveland Medical Center, Cleveland, OH, (6)Montefiore Medical Center, Bronx, NY, (7)Université Libre de Brussels, Brussels, Belgium, (8)Instituto Dante Pazzanese de Cardiologia, Sao Paulo, Brazil, (9)Freeman Hospital and Newcastle University, Newcastle upon Tyne, United Kingdom, (10)Medtronic, Santa Rosa, CA, (11)The University of Bern, Bern, Switzerland, (12)Icahn School of Medicine at Mount Sinai, New York City, NY
Keywords: Acute Coronary Syndromes (ACS), Coronary, Drug-eluting Stent (DES) and Women's Health
Background
While dual antiplatelet therapy (DAPT) constitutes the cornerstone of post-PCI pharmacotherapy, duration of DAPT in high bleeding risk (HBR) patients has not been fully defined especially with regard to sex. The results from the Onyx ONE Clear trial demonstrated favorable safety and efficacy after PCI with 1-month dual antiplatelet therapy (DAPT) in HBR patients treated with Resolute Onyx drug-eluting stents (DES). We sought to evaluate impact of sex on clinical outcomes in this trial.
Methods
In this prespecified subgroup analysis from Onyx ONE Clear, patients were divided into 2 groups according to sex. Primary endpoint was cardiac death or myocardial infarction (MI) from 1 month to 1 year.
Results
A total of 487 female patients (32%) and 1019 males (68%) were free from major ischemic events 1-month after PCI and were transitioned to single antiplatelet therapy. Women were older (p<0.001), had more HBR criteria (p=0.02), and higher rates of moderate/severe calcific lesions (p=0.03) compared to men. Men had higher rates of previous MI (p=0.003), atrial fibrillation (p=0.001), and multivessel coronary artery disease (p<0.001). Clinical outcomes between 1 and 12 months are shown in (
Figure) and were similar for males and females except for target vessel revascularization which was greater for males (p=0.04).
Conclusions
In HBR patients treated with Resolute Onyx DES and an abbreviated DAPT course of one month, rates of the primary endpoint of cardiac death or MI between 1 and 12 months were low and did not show any sex-based differences. These data support the use of an abbreviated DAPT regimen in men and women with HBR after PCI with Resolute Onyx DES.
